Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week
NCT ID: NCT00537888
Last Updated: 2010-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
200 participants
INTERVENTIONAL
2007-09-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fluconazole
Intravenous or oral 400 md/d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* APACHE II\<25
* Lung infiltrates together with at least one of the following symptoms:cough, sputum, dyspnea with or without fever
* smear or culture positive for candida spp. from sputum
Exclusion Criteria
* Hypersensitivity to fluconazole
* Isolated candida was non-sensitive to fluconazole
* Severe liver or renal diseases who can not tolerate fluconazole treatment
* With at least one of the following high risk factors:organ transplantation, neutropenia\>10ds, long term glucocorticoids therapy(equal to prednisone 30mg/d longer than 2 weeks), immunosuppressive therapy within 30ds, AIDS
* With one of the microbiological evidence:isolation of candida spp. from blood or other kinds of sterile site(not including urine), filamentous fungi isolated from sputum or BALF, cryptococcus isolated from sputum or CSF, galactomannan antigen positive twice for blood
* Probable or possible pulmonary aspergillosis
* Definite oral or esophageal candidiasis
14 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Capital Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beijing Chaoyang Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bin Cao, Doctor
Role: PRINCIPAL_INVESTIGATOR
Beijing Chaoyang Hospital, Affiliate of Capital Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chaoyang Hospital,Affiliate of Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bin Cao, doctor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Cao B, Cai BQ, Wang H, Zhou CY, Wang P, Liu HR, Zhang H, Xu L, Xu KF, Xu WB, Zhu YJ, Li XG. [A study of 152 cases of pulmonary fungal infection: reevaluation of the microbiological spectra]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Apr;30(4):279-83. Chinese.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CYH-CMU
Identifier Type: -
Identifier Source: org_study_id